Novo Nordisk: Undervalued Amidst a Billion-Patient Market Opportunity

I am initiating coverage of Novo Nordisk with a Strong Buy rating. The stock has fallen to a decade-low valuation and has a large market of over a billion patients. I have been accumulating the stock on multiple occasions since it fell below DKK 400. The rationale for this rating includes the company's strong position in the diabetes market and its potential for growth in the future.